Karl Rotthier (Belgian) holds a Master of Laws from the University of Antwerp (Belgium) and the University of Southampton (UK), and an MBA from Vlerick Business School (Belgium).
Prior to joining DSM and subsequently DSM Sinochem Pharmaceuticals (DSP), Karl has been active as a lawyer in Belgium and worked for BASF in Belgium and Germany, leading, amongst others, the Performance Chemicals business unit of BASF in Ludwigshafen.
Karl joined DSM in 2005 as Director Special Projects, focusing on pricing and later joined DPP as Business Unit Director Exclusive Synthesis/Intermediates. In 2009, Karl joined DSP as the Business Unit Director Europe/Americas.
On 1 January, 2011, Karl became Chief Operating Officer responsible for the Running Business and Operations worldwide. In July 2014, Karl became the President of DSP, in charge of the global business of DSP.
In 2016 Karl was appointed Chief Executive Officer of DSM Sinochem Pharmaceuticals.
Chief Financial Officer
Bart Welten (Dutch) holds a law degree from Leiden University (Netherlands) and an MBA from Boston College (USA).
Bart started his career as a management consultant in Amsterdam and later joined Royal Gist-brocades in Delft. At Gist-brocades Bart was Finance Director Italy, Business Group Controller of Bio Specialties and later of Food Specialties. After the acquisition of Gist-brocades by DSM, he became interim CFO for Catalytica Pharmaceuticals in North Carolina and subsequently was the finance project leader for the acquisition of Roche Vitamins in 2003.
After a brief period outside DSM as CFO of Kiadis Pharma, Bart returned to DSM where he worked at DSM Anti-Infectives (today DSM Sinochem Pharmaceuticals) and as CFO of DSM Resins.
In 2011 Bart was appointed as Chief Finance Officer of DSP Sinochem Pharmaceuticals.
Lu Fang Bin
Chief Strategy Officer
Mr. Lu Fang Bin (Chinese) holds a master’s degree in Chemical Engineering from Tsinghua University (China).
Fang Bin brings more than 20 years of professional experience ranging from the plastics and importing business to leading Sinochem’s business in the US. His most recent position was Deputy General Manager of Sinofert.
In 2017 Mr. Lu Fang Bin was appointed Chief Strategy Officer of DSM Sinochem Pharmaceuticals.
Chief Human Resources Officer
Gary Yeo (Singaporean) holds a bachelor degree in Economics from the National University Singapore and a Master of Science Degree in Human Resources Management from Rutgers University (USA).
Gary has almost 3 decades of experience in the Human Resources function, having worked in companies like General Electric, Novartis and Johnson & Johnson, covering Asia Pacific as well Europe and Latin America.
In 2013 Gary was appointed Chief Human Resources Officer of DSM Sinochem Pharmaceuticals.
Vice President Operations & Technology
Rajesh Salwan (Indian) studied Chemical Engineering at Osmania University (India) and Business Administration at IMT (India).
Rajesh started his career as Process Engineer with Max Gb (India). In 1999 he joined Monsanto as project manager for South East Asia and later moved to a plant manager role.
In 2002 Rajesh joined DSM Anti-Infectives as large Capital Project Manager where he led several construction and business projects. In 2008 he became site Director and subsequently in 2010 Operations Director for India leading Manufacturing, DSCM, Sourcing & Regulatory Affairs.
In 2015 Rajesh was appointed Vice President Operations & Technology of DSM Sinochem Pharmaceuticals.
Head of Global Business
Global Product Owner Penicillins, SSCs, new API and Nystatin
Business Unit Director Europe/America and Asia, Middle East and Africa ad interim
Director New API
Frans Vlaar (Dutch) holds a Master of Science in Chemical Engineering from the Delft University of Technology.
After joining DSM in 1990, Frans worked in multiple roles such as project leader, corporate recruiter, area sales manager and ultimately global product manager in 2002. In 1997 he joined DSM Anti-Infectives, the predecessor of DSM Sinochem Pharmaceuticals (DSP) in Delft (Netherlands) as Business Director.
In 2012 Frans was appointed Business Unit Director Europe/America of DSP (a 50/50 joint venture between DSM and Sinochem), responsible for all activities of DSP in Europe and North America. Since 2014 he is also responsible for a new Unit called “New Active Pharmaceutical Ingredients”, leading the development of new molecules for DSP.
In 2016 Frans was appointed Global Product Owner Penicillins, SSCs, Nystatin at DSM Sinochem Pharmaceuticals.
Global Product Owner SSPs
Business Unit Director Mexico and Latin America
Maarten Pouw (Dutch) holds a Master of Science in Business Administration from the Rotterdam School of Management and a CEMS Master of International Management.
He started his career in management consulting working for several companies in various industries with a focus on project management & marketing.
In 2006 Maarten joined DSM Anti-Infectives, the predecessor of DSM Sinochem Pharmaceuticals (DSP) in Delft (The Netherlands) as Product Manager. In 2011 he relocated to the USA to set up the North American sales office and expand the business. In addition he has performed various roles within Marketing and Business Development functions supporting the commercial area of Europe/America.
In 2014 Maarten was appointed Business Unit Director Mexico Latin America of DSM Sinochem Pharmaceuticals.
In 2016 Maarten was appointed Global Product Owner semi-synthetic penicillins.
Business Unit Director Drug Products (ad interim)
Global Strategy Director Drug Products
Lucas Wiarda (Dutch) holds an Executive Master in Finance and Control from the Amsterdam Business School and a Master of Finance from the University of Amsterdam.
Prior to joining DSM and subsequently DSM Sinochem Pharmaceuticals, he held financial functions at VNU and The Nielsen Company, and worked on a voluntary basis as Program Director for the United Nations World Food Program in Bangladesh.
After joining DSM Sinochem Pharmaceuticals (DSP) in 2008, Lucas performed various roles, among which Global Marketing Director and Head of the Sustainable Antibiotics Program. Lucas played a key role in establishing the Industry Roadmap on Antimicrobial Resistance (AMR) and is a member of the AMR Industry Alliance Board.
On 30 October 2017, Lucas was appointed Director for the Business Unit Drug Products (ad interim).